Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled Trials

被引：0
|
作者：
Craig Leonardi
Kristian Reich
Peter Foley
Hideshi Torii
Sascha Gerdes
Lyn Guenther
Melinda Gooderham
Laura K. Ferris
Christopher E. M. Griffiths
Hany ElMaraghy
Heidi Crane
Himanshu Patel
Russel Burge
Gaia Gallo
David Shrom
Ann Leung
Chen-Yen Lin
Kim Papp
机构：
[1] Central Dermatology,Center for Translational Research in Inflammatory Skin Diseases, Institute for Health Services Research in Dermatology and Nursing
[2] University Medical Center Hamburg-Eppendorf,St. Vincent’s Hospital Melbourne and Probity Medical Research, Skin Health Institute
[3] Skinflammation® Center,Division of Dermatology
[4] The University of Melbourne,Psoriasis
[5] Tokyo Yamate Medical Center,Center at the Department of Dermatology
[6] University Medical Center Schleswig-Holstein,Dermatology Centre, Salford Royal Hospital
[7] Guenther Dermatology Research Centre,undefined
[8] SkiN Centre for Dermatology and Probity Medical Research,undefined
[9] University of Pittsburgh Medical Center,undefined
[10] University of Manchester,undefined
[11] Eli Lilly and Company,undefined
[12] Lilly Corporate Center,undefined
[13] Syneos Health,undefined
[14] K. Papp Clinical Research and Probity Medical Research Inc.,undefined
来源：
Dermatology and Therapy | 2020年 / 10卷
关键词：
Ixekizumab; Long-term efficacy; Long-term safety; Maintain; Psoriasis; Quality of life; 5 years;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：431 / 447
页数：16
相关论文
共 50 条
  • [41] Efficacy of baricitinib in patients with moderate-to-severe rheumatoid arthritis with 3 years of treatment: results from a long-term study
    Smolen, Josef S.
    Xie, Li
    Jia, Bochao
    Taylor, Peter C.
    Burmester, Gerd
    Tanaka, Yoshiya
    Elias, Ayesha
    Cardoso, Anabela
    Ortmann, Rob
    Walls, Chad
    Dougados, Maxime
    RHEUMATOLOGY, 2021, 60 (05) : 2256 - 2266
  • [42] Bimekizumab safety in patients with moderate-to-severe plaque psoriasis: pooled data from up to 3 years of treatment in randomized phase III trials
    Gordon, Kenneth B.
    Langley, Richard G.
    Warren, Richard B.
    Okubo, Yukari
    Rosmarin, David
    Lebwohl, Mark
    Peterson, Luke
    Madden, Cynthia
    de Cuyper, Dirk
    Davies, Owen
    Thaci, Diamant
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 190 (04) : 477 - 485
  • [43] Long-term efficacy and safety of tildrakizumab in Japanese patients with moderate to severe plaque psoriasis: Results from a 5-year extension of a phase 3 study (reSURFACE 1)
    Imafuku, Shinichi
    Nakagawa, Hidemi
    Igarashi, Atsuyuki
    Morita, Akimichi
    Okubo, Yukari
    Sano, Shigetoshi
    Tada, Yayoi
    Nemoto, Osamu
    Rozzo, Stephen J.
    Kawamura, Masaki
    Ohtsuki, Mamitaro
    JOURNAL OF DERMATOLOGY, 2021, 48 (06) : 844 - 852
  • [44] Safety and efficacy of bimekizumab through 2 years in patients with moderate-to-severe plaque psoriasis: longer-term results from the BE SURE randomized controlled trial and the open-label extension from the BE BRIGHT trial
    Thaci, Diamant
    Vender, Ron
    de Rie, Menno A.
    Conrad, Curdin
    Pariser, David M.
    Strober, Bruce
    Vanvoorden, Veerle
    Wang, Maggie
    Madden, Cynthia
    de Cuyper, Dirk
    Kimball, Alexa B.
    BRITISH JOURNAL OF DERMATOLOGY, 2023, 188 (01) : 22 - 31
  • [45] Safety of Ixekizumab Treatment for up to 5 Years in Adult Patients with Moderate-to-Severe Psoriasis: Results from Greater Than 17,000 Patient-Years of Exposure
    April Armstrong
    Carle Paul
    Luis Puig
    Wolf Henning Boehncke
    Michael Freeman
    Hideshi Torii
    Kim Papp
    Christopher E. M. Griffiths
    Andrew Blauvelt
    Kristian Reich
    Melinda Gooderham
    Tadashi Terui
    Lisa Renda
    Noah Agada
    Wen Xu
    Gaia Gallo
    Mark G. Lebwohl
    Dermatology and Therapy, 2020, 10 : 133 - 150
  • [46] Efficacy and safety of apremilast in pediatric patients with moderate-to-severe plaque psoriasis: 16-week results from SPROUT, a randomized controlled trial
    Fiorillo, Loretta
    Becker, Emily
    de Lucas, Raul
    Belloni-Fortina, Anna
    Armesto, Susana
    Elewski, Boni
    Maes, Peter
    Oberoi, Rajneet K.
    Paris, Maria
    Zhang, Wendy
    Zhang, Zuoshun
    Arkin, Lisa
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2024, 90 (06) : 1232 - 1239
  • [47] Long-term (1 year) efficacy of etanercept in moderate-to-severe psoriasis. Results of a multicentric observational study in Spain
    Lluís Puig
    Francisco Camacho
    Vicente García-Patos
    Maria Luisa Fernández-Díaz
    Amparo Marquina
    Carmen García-Calvo
    European Journal of Dermatology, 2015, 25 : 410 - 417
  • [48] Long-term (1 year) efficacy of etanercept in moderate-to-severe psoriasis. Results of a multicentric observational study in Spain
    Puig, Lluis
    Camacho, Francisco
    Garcia-Patos, Vicente
    Luisa Fernandez-Diaz, Maria
    Marquina, Amparo
    Garcia-Calvo, Carmen
    EUROPEAN JOURNAL OF DERMATOLOGY, 2015, 25 (05) : 410 - 417
  • [49] Efficacy and safety of adalimumab in Chinese patients with moderate-to-severe plaque psoriasis: results from a phase 3, randomized, placebo-controlled, double-blind study
    Cai, L.
    Gu, J.
    Zheng, J.
    Zheng, M.
    Wang, G.
    Xi, L. -Y.
    Hao, F.
    Liu, X. -M.
    Sun, Q. -N.
    Wang, Y.
    Lai, W.
    Fang, H.
    Tu, Y. -T.
    Sun, Q.
    Chen, J.
    Gao, X. -H.
    Gu, Y.
    Teixeira, H. D.
    Zhang, J. -Z.
    Okun, M. M.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2017, 31 (01) : 89 - 95
  • [50] Long-term efficacy of tildrakizumab in patients with moderate-to-severe psoriasis who were responders at week 28: pooled analysis through 148 weeks from two phase 3 trials
    Thaci, D.
    Iversen, L.
    Pau-Charles, I.
    Igarashi, A.
    Ohtsuki, M.
    Rozzo, S.
    Lebwohl, M.
    Cantrell, W.
    Blauvelt, A.
    Reich, K.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2019, 33 : 53 - 53
12345